bcdiabetes.ca
Patient Care + Research + Clinical Trials

Dr. Tom Elliott MBBS, FRCPC
Medical Director

400 - 210 W Broadway
Vancouver, BC
V5Y 3W2 Canada

phone: 604.683.3734
fax: 604.628.3821
email: moa@bcdiabetes.ca

Oral GLP1 in Participants Type 2 Diabetes (Eluminate 2)

Study location BCDiabetes: 400 - 210 West Broadway, Vancouver V5Y 3W2
Principal Investigators Dr. Tom Elliott
SubInvestigators : Dr Dale Clayton and Dr Dae Won (David) Lee
SC & Primary Contact Marla Inducil MD P: 604-628-7253 x 7011 : minducil@bcdiabetes.ca
Back up SC: Hector Com MD ; Glaiza Erfe MD; Alireza Moshiri MD

Summary: The purpose of this 58 week trial is to evaluate the efficacy, safety, and tolerability of once-daily oral administration of elecoglipron, a small molecule, compared with oral semaglutide, a peptide molecule, in adults with type 2 diabetes mellitus (T2DM) with increased cardiovascular risk that is inadequately managed with a stable dose of up to 2 oral T2DM medications.

Hypothesis: Elecoglipron, a novel small-molecule oral GLP-1 RA, is anticipated to provide efficacy and safety comparable to other GLP-1 RAs but with the added convenience of oral administration and no fasting requirements, thus potentially improving access and adherence to therapy.The established pharmacology of GLP-1 RAs, including semaglutide, along with data from elecoglipron early clinical studies, supports the expectation that elecoglipron will provide benefits in both glycemic control and weight loss. Participants may also experience improved metabolic control such as reductions in lipids and BP.

Eligible Participants include

- ≥ 18 yrs of age
- T2DM (treatment naive or up to 2 oral hypoglycemic agents
- A1c 7% to ≤ 10.5%
- At least 1 CV risk or 2 CV risk factors
- BMI ≥ 23 kg/m2

Odds of receiving active drug: 1:1 - 65 mg elecoglipron: 9 mg semaglutide



Study documents:
Informed Consent:
Short URL : https://bit.ly/3Pbtvl3